Recent News

• 03.25.2025 - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
• 03.25.2025 - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
• 03.05.2025 - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
• 03.05.2025 - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
• 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
• 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
• 01.10.2025 - iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
• 01.10.2025 - iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
• 01.08.2025 - iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.08.2025 - iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.05.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.13.2025 - EX-99.1 EX-99.1
• 01.13.2025 - 8-K Current report